 Emergent BioSolutions Inc NYSE: EBS has signed a five-year agreement with Providence Therapeutics valued at about 90 million to develop and manufacture its COVID-19 vaccine candidate. Emergent will produce drug substances for Providences vaccine candidate, PTX-COVID19-B, and provide services for finished products at its Winnipeg facility in Canada. 